IP Library Granted Patent US 8,188,042
Granted Patent B1
US 8,188,042 · App. 12/589,300 · Granted May 29, 2012

Nanoparticles for protein drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,042
App. No.
12/589,300
Granted
May 29, 2012
Kind
B1
Abstract

The invention discloses bioactive nanoparticles composed of chitosan, poly-glutamic acid, and diethylenetriaminepentaacetic acid for use in radionuclide decorporation during radiological emergency. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Claims (20)

1. A method of enhancing radionuclide decorporation in a subject comprising administering bioactive nanoparticles to said subject, wherein said nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains a negatively charged substrate, wherein said negatively charged substrate is at least partially neutralized with a portion of said positively charged chitosan and at least one radionuclide-chelating agent.

2. The method of claim 1 , wherein the chitosan has a molecular weight about 80 kDa or less.

3. The method of claim 1 , wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers.

4. The method of claim 1 , wherein the chitosan is N-trimethyl chitosan.

5. The method of claim 1 , wherein said nanoparticles are formed via a simple and mild ionic-gelation process.

6. The method of claim 1 , wherein said nanoparticles are loaded in tablets or pills.

7. The method of claim 6 , wherein said tablets or pills are treated with an enteric polymer.

8. The method of claim 1 , wherein said nanoparticles are encapsulated in capsules.

9. The method of claim 8 , wherein said capsules further comprise at least a solubilizer or pharmacopoeial excipients.

10. The method of claim 8 , wherein said capsules are treated with an enteric polymer.

11. The method of claim 8 , wherein said capsules further comprise at least one permeation enhancer.

12. The method of claim 11 , wherein said permeation enhancer is a Ca 2+ chelator.

13. The method of claim 8 , wherein said capsules further comprise diethylene triamine pentaacetic acid (DTPA).

14. The method of claim 1 , wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form.

15. The method of claim 1 , wherein said nanoparticles are mixed with trehalose and then freeze-dried, thereby said nanoparticles being in a powder form.

16. The method of claim 1 , wherein said nanoparticles further comprise zinc.

17. The method of claim 1 , wherein said at least one radionuclide-chelating agent is diethylene triamine pentaacetic acid (DTPA).

18. The method of claim 1 , wherein said negatively charged substrate is a derivative of PGA.

19. The method of claim 1 , wherein said nanoparticles further comprise at least one permeation enhancer.

20. The method of claim 19 , wherein said permeation enhancer is a Ca 2+ chelator.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2016
From: GP MEDICAL, INC
To: NANOMEGA MEDICAL CORPORATION
Reel/Frame 038382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2010
From: SUNG, HSING-WEN; TU, HOSHENG
To: GP MEDICAL, INC.
Reel/Frame 024716/0195 →